These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 16493188)
1. QT PRODACT: in vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. Tashibu H; Miyazaki H; Aoki K; Akie Y; Yamamoto K J Pharmacol Sci; 2005; 99(5):473-86. PubMed ID: 16493188 [TBL] [Abstract][Full Text] [Related]
2. QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals. Toyoshima S; Kanno A; Kitayama T; Sekiya K; Nakai K; Haruna M; Mino T; Miyazaki H; Yano K; Yamamoto K J Pharmacol Sci; 2005; 99(5):459-71. PubMed ID: 16493187 [TBL] [Abstract][Full Text] [Related]
3. QT PRODACT: in vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. Ando K; Hombo T; Kanno A; Ikeda H; Imaizumi M; Shimizu N; Sakamoto K; Kitani S; Yamamoto Y; Hizume S; Nakai K; Kitayama T; Yamamoto K J Pharmacol Sci; 2005; 99(5):487-500. PubMed ID: 16493189 [TBL] [Abstract][Full Text] [Related]
4. Safety pharmacology assessment of drug-induced QT-prolongation in dogs with reduced repolarization reserve. Vormberge T; Hoffmann M; Himmel H J Pharmacol Toxicol Methods; 2006; 54(2):130-40. PubMed ID: 16757186 [TBL] [Abstract][Full Text] [Related]
5. QT PRODACT: inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys. Sasaki H; Shimizu N; Suganami H; Yamamoto K J Pharmacol Sci; 2005; 99(5):513-22. PubMed ID: 16493191 [TBL] [Abstract][Full Text] [Related]
6. QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. Omata T; Kasai C; Hashimoto M; Hombo T; Yamamoto K J Pharmacol Sci; 2005; 99(5):531-41. PubMed ID: 16493193 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of drug-induced QT prolongation in a halothane-anesthetized monkey model: effects of sotalol. Ishizaka T; Yoshimatsu Y; Ozawa M; Kimotsuki T; Takasaki W; Manabe S; Yasuda M J Pharmacol Toxicol Methods; 2009; 59(2):86-93. PubMed ID: 19367688 [TBL] [Abstract][Full Text] [Related]
8. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs. Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993 [TBL] [Abstract][Full Text] [Related]
9. QT PRODACT: inter- and intra-facility variability of the action potential assay using isolated guinea-pig papillary muscles. Yamazaki R; Yamada M; Kobayashi K; Kitani S; Shimada C; Shimosato T; Mori T; Suganami H; Yamamoto K J Pharmacol Sci; 2005; 99(5):439-47. PubMed ID: 16493185 [TBL] [Abstract][Full Text] [Related]
10. QT PRODACT: usability of miniature pigs in safety pharmacology studies: assessment for drug-induced QT interval prolongation. Kano M; Toyoshi T; Iwasaki S; Kato M; Shimizu M; Ota T J Pharmacol Sci; 2005; 99(5):501-11. PubMed ID: 16493190 [TBL] [Abstract][Full Text] [Related]
11. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative. Hashimoto K Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227 [TBL] [Abstract][Full Text] [Related]
12. Halothane-anaesthetized, closed-chest, guinea-pig model for assessment of drug-induced QT-interval prolongation. Sakaguchi Y; Takahara A; Nakamura Y; Akie Y; Sugiyama A Basic Clin Pharmacol Toxicol; 2009 Jan; 104(1):43-8. PubMed ID: 18699795 [TBL] [Abstract][Full Text] [Related]
13. QT PRODACT: sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation. Miyazaki H; Watanabe H; Kitayama T; Nishida M; Nishi Y; Sekiya K; Suganami H; Yamamoto K J Pharmacol Sci; 2005; 99(5):523-9. PubMed ID: 16493192 [TBL] [Abstract][Full Text] [Related]
14. ILSI-HESI cardiovascular safety subcommittee dataset: an analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc). Chiang AY; Bass AS; Cooper MM; Engwall MJ; Menton RG; Thomas K J Pharmacol Toxicol Methods; 2007; 56(2):95-102. PubMed ID: 17588780 [TBL] [Abstract][Full Text] [Related]
15. Heart rate correction models to detect QT interval prolongation in novel pharmaceutical development. Markert M; Shen R; Trautmann T; Guth B J Pharmacol Toxicol Methods; 2011; 64(1):25-41. PubMed ID: 21635956 [TBL] [Abstract][Full Text] [Related]
16. Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation. Takahara A; Sugiyama A; Hashimoto K Br J Pharmacol; 2005 Oct; 146(4):561-7. PubMed ID: 16056235 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs. Ollerstam A; Visser SA; Duker G; Forsberg T; Persson AH; Nilsson LB; Björkman JA; Gabrielsson J; Al-Saffar A J Pharmacol Toxicol Methods; 2007; 56(2):131-44. PubMed ID: 17689270 [TBL] [Abstract][Full Text] [Related]
18. Sensitivity of inhalation anesthetics isoflurane and sevoflurane for the drug-induced QT-interval prolongation in guinea pigs. Nagasawa Y; Sakai K; Kurimoto R; Kawakami S; Aimoto M; Takahara A J Pharmacol Sci; 2020 May; 143(1):39-44. PubMed ID: 32151542 [TBL] [Abstract][Full Text] [Related]
19. The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model. Morissette P; Nishida M; Trepakova E; Imredy J; Lagrutta A; Chaves A; Hoagland K; Hoe CM; Zrada MM; Travis JJ; Zingaro GJ; Gerenser P; Friedrichs G; Salata JJ J Pharmacol Toxicol Methods; 2013; 68(1):137-49. PubMed ID: 23649000 [TBL] [Abstract][Full Text] [Related]